{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-006015","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.976825+00:00","generated_at":"2026-05-16T08:22:15.579949+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocular Therapeutix CFO Donald Notman takes temporary medical leave; Jason Robins appointed interim CFO","bullets":["Effective Jan 20, 2026, CFO/COO Donald Notman on temporary leave; Jason Robins named interim CFO and principal financial/accounting officer.","Robins granted option to purchase 33,000 shares at $11.45/share, vesting monthly over four years.","Robins, age 49, was SVP Finance since Jan 2025; previously VP Finance at Fusion Pharmaceuticals (acquired by AstraZeneca).","No family relationships or related party transactions with Robins; standard indemnification agreement executed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-006015","json":"https://secwatch.observer/filing/0001104659-26-006015.json","markdown":"https://secwatch.observer/filing/0001104659-26-006015.md","text":"https://secwatch.observer/filing/0001104659-26-006015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926006015/0001104659-26-006015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926006015/tm263902d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:22:15.579949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}